Wc. Wood et al., DOSE AND DOSE INTENSITY OF ADJUVANT CHEMOTHERAPY FOR STAGE-II, NODE-POSITIVE BREAST-CARCINOMA, The New England journal of medicine, 330(18), 1994, pp. 1253-1259
Background. Adjuvant chemotherapy is widely used for breast cancer and
is known to extend survival. Some clinicians seek a greater survival
benefit by increasing the intensity of the dose, whereas others lower
it to diminish toxicity.Methods. The Cancer and Leukemia Group B (CALG
B) conducted a randomized trial of different levels of doses and dose
intensity (dose per unit of time) of adjuvant chemotherapy in 1572 wom
en with node-positive, stage II breast cancer who were assigned to thr
ee treatment groups. One group received 400 mg of cyclophosphamide per
square meter of body-surface area and 40 mg of doxorubicin per square
meter once every 28 days and 400 mg of fluorouracil per square meter
twice every 28 days, for six cycles. Another group received 50 percent
higher doses of the three drugs (600 mg, 60 mg, and 600 mg, respectiv
ely) but for only four cycles, so that the total dose was identical in
these two groups but the dose intensity was higher in the second. The
third group of women received half the total dose used in the other t
wo groups and at half the dose intensity used in the second group. Res
ults. After a median of 3.4 years of follow-up, the women treated with
a high or moderate dose intensity had significantly longer disease-fr
ee survival (P<0.001) and overall survival (P = 0.004) than those trea
ted with a low dose intensity, in three-way log-rank comparisons. Howe
ver, the difference in survival between the two groups treated with a
moderate or high dose intensity was not significant. These results are
consistent with either a dose-response effect or a threshold level of
the dose or dose intensity. Conclusions. The doses of chemotherapy us
ed to treat breast cancer, especially early breast cancer, should not
be reduced if the maximal benefit is to be achieved.